Article
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.
Science translational medicine - 25 Oct 2017
Michelakis Evangelos D, Gurtu Vikram, Webster Linda, Barnes Gareth, Watson Geoffrey, Howard Luke, Cupitt John, Paterson Ian, Thompson Richard B, Chow Kelvin, O'Regan Declan P, Zhao Lan, Wharton John, Kiely David G, Kinnaird Adam, Boukouris Aristeidis E, White Chris, Nagendran Jayan, Freed Darren H, Wort Stephen J, Gibbs J Simon R, Wilkins Martin R
Abstract excerpt
Pulmonary arterial hypertension (PAH) is a progressive vascular disease with a high mortality rate. It is characterized by an occlusive vascular remodeling due to a pro-proliferative and antiapoptotic environment in the wall of resistance pulmonary arteries (PAs). Proliferating cells exhibit a cancer-like metabolic switch where mitochondrial glucose oxidation is suppressed, whereas glycolysis is up-regulated as...
Topics
Join the communities discussing this publication.
